Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
A new initiative launched March 18 by the Dr. Lorna Breen Heroes' Foundation seeks to improve mental health care access for health care workers. The program,…
Headline
A study published Feb. 26 by JAMA Psychiatry found that female physicians died by suicide at more than 1.5 times the rate of female nonphysicians from 2017-…
Headline
The AHA voiced support for bipartisan House legislation introduced Feb. 4 to reauthorize for five years the Dr. Lorna Breen Health Care Provider Protection Act…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
The AHA Jan. 28 voiced support for bipartisan legislation to reauthorize for five years the Dr. Lorna Breen Health Care Provider Protection Act, which provides…
Headline
Perinatal mental health disorders affect countless mothers during pregnancy and postpartum, yet access to comprehensive care remains a challenge. Hospitals are…